Short-term mortality in older (≥70 years) patients with early breast cancer treated with neo‐/adjuvant chemotherapy: A Swedish nationwide retrospective population-based study

The short-term mortality rate at first year after diagnosis among older (≥70 years) patients with breast cancer was relatively low. The higher risk among patients treated with neoadjuvant chemotherapy could be attributed to residual confounding and deserves further evaluation. The low risk of potential treatment-associated death suggests that chemotherapy in this respect is safe, and older patients should not be disqualified for this treatment.